ClinicalTrials.gg
CompletedNCT04362566Updated Oct 14, 2026Results posted

Bupivacaine for Post-operative Pain in Mohs

A Phase 4 interventional study of Bupivacaine and Placebo Saline in Pain, Postoperative and Narcotic Use, sponsored by University of Missouri-Columbia. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by University of Missouri-Columbia · Phase 4, Interventional, and Treatment

How we know

Updated Oct 14, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
174
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 364 studies testing bupivacaine in Pain, Postoperative — 57 open to participants now, 60 under way, 5 of them phase 3. Bupivacaine · Pain, Postoperative.

Enrollment
42nd of 364
174 · median 70
Started
2020
with 16 others
Phase 4
133 of 364
18 open now
Registered
201st of 364
by date

Among the 364 studies testing bupivacaine in Pain, Postoperative, this one is the 42nd largest by enrollment, is one of 17 that started in 2020, is one of 133 in phase 4, and was the 201st registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

57 of the 364 studies testing bupivacaine in Pain, Postoperative are open now, in 8 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About bupivacaine

Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 364 studies testing bupivacaine in Pain, Postoperative, or all of them as a file.
02

Study summary

Mohs micrographic surgery (MMS) is regarded as the gold standard for the treatment of high-risk nonmelanoma skin cancer (NMSC). Pain after MMS peaks on the day of surgery and slowly decreases thereafter. The most common post-operative analgesics include acetaminophen, ibuprofen and narcotics. Lidocaine is the most commonly used anesthetic in MMS, but bupivacaine has been shown in other surgical specialties to be an effective adjuvant to reduce post-operative pain and opioid use when injected locally in the immediate postoperative period. Bupivacaine has also been shown to reduce intra-operative pain during MMS. The investigators plan a single-blinded prospective, randomized, controlled trial to determine if post-operative wound infiltration of bupivacaine versus normal saline improves post-operative pain and decreases need for post-operative pain medications including both narcotic and nonnarcotic analgesics.

Read the detailed description

Mohs micrographic surgery (MMS) is the first-line treatment for high-risk nonmelanoma skin cancer (NMSC) and is increasingly used for melanoma and other cutaneous neoplasms. The surgical technique involves multiple stages of surgery followed by reconstruction and is typically performed under local anesthesia in the office setting in one day.

MMS is generally well tolerated, but post-operative pain is common. Pain peaks on the day of surgery and slowly declines in subsequent days. Risk factors for increased pain may include flap or graft repair type, location on scalp, lip, nose, or ear, younger age, and increased number of lesions treated. Post-operative pain medication is not standardized in dermatological surgery, but often includes non-narcotic analgesics including acetaminophen and ibuprofen, and less commonly narcotic analgesics such as tramadol and oxycodone. Given the current national trend to reduce opioid use, a multimodal approach to pain management has been adopted by many surgical specialties to optimize analgesia perioperatively.

The most commonly used anesthetic in MMS is local subcutaneous infiltration of lidocaine 0.5 - 2% with 1:100,000 - 1:200,000 epinephrine. Lidocaine is quick-acting, can be buffered to reduce injection pain, and is well tolerated, but the duration of action is only two hours, making it less effective for post-operative pain. Bupivacaine with epinephrine has a longer duration of action compared to lidocaine (up to four hours), but it is rarely used alone due to slower onset of action and more painful injection compared with lidocaine. Bupivacaine is used in many other surgical specialties, including general, plastic, and orthopedic surgery, as a peri-operative adjuvant and has been shown to reduce post-operative opioid use. It is generally well tolerated, carrying a class-effect risk of cardiac toxicity in high doses as does lidocaine, but has been shown to be safe in dermatologic surgery when used for wound infiltration. A newer formulation of liposomal bupivacaine has been shown to be even longer lasting and safer, with pain control up to 72 hours and no reported cardiac toxicity. In addition, a recent study has showed subcutaneous infiltration of bupivacaine with epinephrine to be an effective intra-operative pain adjuvant during MMS compared to lidocaine alone.

Pain control post-operatively in MMS may be optimized by including bupivacaine injections at the end of the surgical procedure given its long-lasting anesthetic effects. There are currently no studies addressing the use of bupivacaine as an adjuvant to control post-operative pain during MMS. The investogators propose a prospective randomized controlled trial to evaluate the effectiveness of bupivacaine injection at the conclusion of surgery for reducing post-operative pain and analgesic use.

03

Conditions studied

  • Pain, Postoperative
  • Narcotic Use

Browse trials for

Keywords

  • local anesthetic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • a. Adult (18 years or older) patients being treated with Mohs micrographic surgery will be included in this study.

    b. Surgical procedure must include one of the following:

    1. Scalp rotation/transposition/advancement flap
    2. Ear rotation/transposition/advancement/interpolation flap or wedge repair
    3. Nose rotation/transposition/advancement/interpolation flap, cartilage alar-batten graft (ear donor site)
    4. Cheek Mustarde flap
    5. Lip rotation/transposition/advancement flap, wedge repair, Abbe flap

Exclusion criteria

Exclusion Criteria:

  • c. Patients must not

    1. be pregnant or breastfeeding
    2. be taking scheduled narcotic medications
    3. use narcotics as a drug of abuse
    4. have an allergy to bupivacaine or other amide anesthetics
    5. have a to tramadol
    6. have been given narcotic pain medications during the Mohs procedure or subsequent reconstruction
    7. have multiple surgical sites treated on the same day
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
174 participants (actual)

Study arms

  • Active comparator
    Bupivicaine

    Scalp flap: 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc, Ear flap or wedge repair: 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc Nose flap, 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc. Split volume between nose and donor site for melolabial interpolated flap Paramedian forehead flap: 5cc split between forehead donor site and nasal recipient site: 4cc forehead, 1cc nose Cartilage alar-batten graft (ear donor site) 1cc at auricular donor site in addition to bupivacaine used for nasal reconstruction, if any, that qualifies above Cheek Mustarde flap: 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc Lip flap, wedge repair, Abbe flap: 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc

    Drug: Bupivacaine

  • Placebo comparator
    Placebo saline

    Saline in the same volume as described above for bupivicaine

    Other: Placebo Saline

Interventions

  • Scalp flap: 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc, Ear flap or wedge repair: 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc Nose flap, 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc. Split volume between nose and donor site for melolabial interpolated flap Paramedian forehead flap: 5cc split between forehead donor site and nasal recipient site: 4cc forehead, 1cc nose Cartilage alar-batten graft (ear donor site) 1cc at auricular donor site in addition to bupivacaine used for nasal reconstruction, if any, that qualifies above Cheek Mustarde flap: 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc Lip flap, wedge repair, Abbe flap: 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc

  • OtherPlacebo Saline

    Scalp flap: 2.5cc salinefor 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc, Ear flap or wedge repair: 2.5cc saline for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc Nose flap, 2.5cc saline for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc. Split volume between nose and donor site for melolabial interpolated flap Paramedian forehead flap: 5cc split between forehead donor site and nasal recipient site: 4cc forehead, 1cc nose Cartilage alar-batten graft (ear donor site) 1cc at auricular donor site in addition to saline used for nasal reconstruction, if any, that qualifies above Cheek Mustarde flap: 2.5cc saline for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc Lip flap, wedge repair, Abbe flap: 2.5cc saline for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc

06

What researchers measure

Primary outcomes

  1. 24 Hour Pain Control

    Postoperative pain levels using a Visual Analog Scale of 0-10, where 0 is no pain and 10 is the worst pain, during 24 hours following surgery in the intervention and control groups.

    Time frame: 24 hours post-surgery

Secondary outcomes

  1. 48 Hour Pain Control 0-10 Scale

    Postoperative pain levels using a Visual Analog Scale of 0-10, where 0 is no pain and 10 is the worst pain, during 48 hours following surgery in the intervention and control groups.

    Time frame: 48 hours post surgery

  2. Number of Narcotic Drug Doses Taken to up 48 Hours Post Surgery

    Number of narcotic drug doses (Tramadol 50mg) taken up to 48 hours post surgery for pain management

    Time frame: 48 hours Post Surgery

  3. Adverse Effects

    Documenting adverse effects, if any, from long-acting anesthetic that are different from the placebo group

    Time frame: 72 hours

07

Results

Posted Oct 14, 2026

Participant flow

Participant flow — Overall Study
MilestoneBupivicainePlacebo Saline
Started7987
Completed7987
Not completed00

Outcome measures

Primary24 Hour Pain Control

Postoperative pain levels using a Visual Analog Scale of 0-10, where 0 is no pain and 10 is the worst pain, during 24 hours following surgery in the intervention and control groups.

Time frame:
24 hours post-surgery
Reported as:
Mean · score on a scale
24 Hour Pain Control
score on a scaleBupivicainePlacebo Saline
24 Hour Pain Control1.4 (1 to 3)3 (2 to 4)
Secondary48 Hour Pain Control 0-10 Scale

Postoperative pain levels using a Visual Analog Scale of 0-10, where 0 is no pain and 10 is the worst pain, during 48 hours following surgery in the intervention and control groups.

Time frame:
48 hours post surgery
Reported as:
Mean · score on a scale
48 Hour Pain Control 0-10 Scale
score on a scaleBupivicainePlacebo Saline
48 Hour Pain Control 0-10 Scale2.18 (0.91 to 5.29)3 (1 to 6)
SecondaryNumber of Narcotic Drug Doses Taken to up 48 Hours Post Surgery

Number of narcotic drug doses (Tramadol 50mg) taken up to 48 hours post surgery for pain management

Time frame:
48 hours Post Surgery
Reported as:
Mean · Doses
Number of Narcotic Drug Doses Taken to up 48 Hours Post Surgery
DosesBupivicainePlacebo Saline
Number of Narcotic Drug Doses Taken to up 48 Hours Post Surgery1 (0.5 to 1.5)2.18 (1.08 to 4.41)
SecondaryAdverse Effects

Documenting adverse effects, if any, from long-acting anesthetic that are different from the placebo group

Time frame:
72 hours
Reported as:
Number · Adverse effects
Adverse Effects
Adverse effectsBupivicainePlacebo Saline
Adverse Effects00

Adverse events

Collected over 72 hours. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bupivicaine0/79 (0%)0/79 (0%)0/79 (0%)
Placebo Saline0/87 (0%)0/87 (0%)0/87 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)BupivicainePlacebo SalineTotal
<=18 years000
Between 18 and 65 years5813
>=65 years7479153
Sex: Female, Male
Sex: Female, Male(Participants)BupivicainePlacebo SalineTotal
Female403777
Male395089
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)BupivicainePlacebo SalineTotal
Count of participants——0
08

Study locations

1 site
  • University of Missouri-Columbia
    Columbia, Missouri 65212, United States
09

References and documents

Publications

  • Tolkachjov SN, Brodland DG, Coldiron BM, Fazio MJ, Hruza GJ, Roenigk RK, Rogers HW, Zitelli JA, Winchester DS, Harmon CB. Understanding Mohs Micrographic Surgery: A Review and Practical Guide for the Nondermatologist. Mayo Clin Proc. 2017 Aug;92(8):1261-1271. doi: 10.1016/j.mayocp.2017.04.009. PubMed 28778259 ↗
  • Saco M, Golda N. Postoperative Pain Management in Dermatologic Surgery: A Systematic Review. Dermatol Clin. 2019 Jul;37(3):341-348. doi: 10.1016/j.det.2019.03.004. Epub 2019 Apr 16. PubMed 31084728 ↗
  • Saco M, Golda N. Optimal timing of postoperative pharmacologic pain control in Mohs micrographic surgery: A prospective cohort study. J Am Acad Dermatol. 2020 Feb;82(2):495-497. doi: 10.1016/j.jaad.2019.07.077. Epub 2019 Jul 30. No abstract available. PubMed 31374303 ↗
  • Roy CF, Azzi AJ, Davison P. A Review of Wound Infusion With Local Anesthetics in Plastic Surgery. Ann Plast Surg. 2019 Dec;83(6):e110-e117. doi: 10.1097/SAP.0000000000001916. PubMed 31192870 ↗
  • Dasta J, Ramamoorthy S, Patou G, Sinatra R. Bupivacaine liposome injectable suspension compared with bupivacaine HCl for the reduction of opioid burden in the postsurgical setting. Curr Med Res Opin. 2012 Oct;28(10):1609-15. doi: 10.1185/03007995.2012.721760. Epub 2012 Sep 3. PubMed 22900785 ↗
  • Chen P, Smith H, Vinciullo C. Bupivacaine as an Adjunct to Lidocaine in Mohs Micrographic Surgery: A Prospective Randomized Controlled Trial. Dermatol Surg. 2018 May;44(5):607-610. doi: 10.1097/DSS.0000000000001385. PubMed 29140864 ↗
  • Merritt BG, Lee NY, Brodland DG, Zitelli JA, Cook J. The safety of Mohs surgery: a prospective multicenter cohort study. J Am Acad Dermatol. 2012 Dec;67(6):1302-9. doi: 10.1016/j.jaad.2012.05.041. Epub 2012 Aug 11. PubMed 22892283 ↗
  • Limthongkul B, Samie F, Humphreys TR. Assessment of postoperative pain after Mohs micrographic surgery. Dermatol Surg. 2013 Jun;39(6):857-63. doi: 10.1111/dsu.12166. Epub 2013 Mar 6. PubMed 23464845 ↗
  • Firoz BF, Goldberg LH, Arnon O, Mamelak AJ. An analysis of pain and analgesia after Mohs micrographic surgery. J Am Acad Dermatol. 2010 Jul;63(1):79-86. doi: 10.1016/j.jaad.2009.10.049. PubMed 20542176 ↗
  • Sniezek PJ, Brodland DG, Zitelli JA. A randomized controlled trial comparing acetaminophen, acetaminophen and ibuprofen, and acetaminophen and codeine for postoperative pain relief after Mohs surgery and cutaneous reconstruction. Dermatol Surg. 2011 Jul;37(7):1007-13. doi: 10.1111/j.1524-4725.2011.02022.x. Epub 2011 May 11. PubMed 21561527 ↗
  • Evans T, Nicholas TA, Sutton AV, Wysong A. How We Do It: Postoperative Pain Control in Mohs Micrographic Surgery. Dermatol Surg. 2021 Feb 1;47(2):280-282. doi: 10.1097/DSS.0000000000002279. No abstract available. PubMed 31809346 ↗
  • Lovich-Sapola J, Smith CE, Brandt CP. Postoperative pain control. Surg Clin North Am. 2015 Apr;95(2):301-18. doi: 10.1016/j.suc.2014.10.002. Epub 2015 Jan 24. PubMed 25814108 ↗
  • Park KK, Sharon VR. A Review of Local Anesthetics: Minimizing Risk and Side Effects in Cutaneous Surgery. Dermatol Surg. 2017 Feb;43(2):173-187. doi: 10.1097/DSS.0000000000000887. PubMed 27608208 ↗
  • Kouba DJ, LoPiccolo MC, Alam M, Bordeaux JS, Cohen B, Hanke CW, Jellinek N, Maibach HI, Tanner JW, Vashi N, Gross KG, Adamson T, Begolka WS, Moyano JV. Guidelines for the use of local anesthesia in office-based dermatologic surgery. J Am Acad Dermatol. 2016 Jun;74(6):1201-19. doi: 10.1016/j.jaad.2016.01.022. Epub 2016 Mar 4. PubMed 26951939 ↗
  • Sorenson E, Chesnut C. Liposomal Bupivacaine: A Review and Applications to Dermatologic Surgery. Dermatol Surg. 2019 Jan;45(1):68-73. doi: 10.1097/DSS.0000000000001628. No abstract available. PubMed 30148736 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Patient data will be submitted from University of Pennsylvania and Columbia university to the University of Missouri primary research group for statistical analysis. The IPD will not be shared outside of this research team.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Sep 2021, 14 months.

Results were first posted in Oct 2026, 5 years after primary completion.

Of 535 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's 14 months is below that.

Counting every sponsor, half of 545 studies reached it within 16 months; a quarter within 8 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2020
First posted
Apr 27, 2020
StartActual
Jul 30, 2020
Primary completionActual
Sep 30, 2021
CompletionActual
Sep 30, 2021
Results first posted
Oct 14, 2026
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 14, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • Edited24 Hour Pain controlControlTime frame: 24 hours → 24 hours post-surgery
Oct 14, 2026
Documents
Oct 14, 2026
Secondary outcomes
2 edited, 1 added, 2 removed
What changed in the outcomes
  • Edited48 hour pain control 1Hour Pain Control 0-10 scaleScaleTime frame: 48 hours → 48 hours post surgery
  • EditedAdverse effectsEffectsTime frame: 48 hours → 72 hours
  • AddedNumber of Narcotic Drug Doses Taken to up 48 Hours Post SurgeryTime frame: 48 hours Post Surgery
  • Removed48 hour pain control drug type used if anyTime frame: 48 hours
  • Removed48 hour pain control drug amount used if anyTime frame: 48 hours
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Results posted
    Documents Study protocol ↗ posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • Edited24 Hour Pain controlControlTime frame: 24 hours → 24 hours post-surgery
    Secondary outcomes 2 edited, 1 added, 2 removed
    What changed in the outcomes
    • Edited48 hour pain control 1Hour Pain Control 0-10 scaleScaleTime frame: 48 hours → 48 hours post surgery
    • EditedAdverse effectsEffectsTime frame: 48 hours → 72 hours
    • AddedNumber of Narcotic Drug Doses Taken to up 48 Hours Post SurgeryTime frame: 48 hours Post Surgery
    • Removed48 hour pain control drug type used if anyTime frame: 48 hours
    • Removed48 hour pain control drug amount used if anyTime frame: 48 hours
    + 3 other changes: verification date, responsible party and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04362566
Responsible party
Sponsor
First posted
Apr 27, 2020
Start date
Jul 30, 2020
Primary completion
Sep 30, 2021
Completion
Sep 30, 2021
Results posted
Oct 14, 2026
Last update
Oct 14, 2026

Study contacts

Nicholas J Golda, MD
principal investigator · University of Missouri School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupivacaine

Start the discussion